Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer

Author(s): Reyhaneh Moradi-Marjaneh, Majid Khazaei, Sima Seifi, Seyed Mahdi Hassanian, Gordon A. Ferns, Amir Avan*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 23 , 2018

Become EABM
Become Reviewer
Call for Editor


Inter-individual differences in drug response are an important cause of failure in anticancer treatment and adverse drug events in cancer patients. Gene polymorphisms related to these outcomes have been investigated in an effort to find new genetic biomarkers to predict toxicity and response to anticancer drugs. Evaluating the value single nucleotide polymorphisms (SNPs) in the genes involved in transportation, activation and metabolism of anticancer drugs provides a promising approach to select the appropriate therapeutic regimes with at least adverse reactions. This review summarizes the current knowledge about the relationship between of SNPs involved in the transportation, activation and metabolism of anticancer drugs and treatment outcomes in colorectal cancer (CRC) patients.

Keywords: Colorectal cancer, polymorphisms, anticancer drugs, pharmacogenetics, gene polymorphisms, single nucleotide polymorphisms.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [2710 - 2718]
Pages: 9
DOI: 10.2174/1381612824666180727144535
Price: $65

Article Metrics

PDF: 27
PRC: 1